Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Source: MarketWatch ·
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Read the full story at MarketWatch
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.